Research Study Funded by Bill and Melinda Gates Foundation Confirms the Safety of Continuous Administration of Ivermectin
The FDA warned Americans to never use medications like Ivermectin that “is intended for animals.”
They called it a horse drug.
Now a clinical trial conducted by MedinCells and surprisingly funded by the Bill and Melinda Gates Foundation confirmed the safety of ivermectin taken daily in oral form.
According to the press release, there were no side effects observed with the three doses of ivermectin tested up to 100 μg/kg in continuous administration over 1 month in healthy volunteers.
MedinCell tested ivermectin taken daily in oral form to simulate the continuous release of the active substance by a long-acting injectable. After completion, the study confirms the safety of ivermectin up to a dose of 100 μg / kg / day in continuous administration over 1 month in healthy volunteers. No significant difference was observed between the treated volunteers and the placebo volunteers in the three cohorts studied successively (daily doses of 50 μg / kg, 75 μg / kg and 100 μg / kg respectively).
The pharmacokinetic data of the three cohorts shows a limited peak circulating plasma concentration in the first 12 hours (Cmax between 25-60 ng / mL) and the rapid achievement of a stationary regime and a regular plasma concentration of between approximately 10 and 30 ng / mL for 28 days, depending on the dose administered. These preliminary results are considered positive and live up to Company expectations based on the data in the literature. The dose-response relationship has not yet been established.
The study started last September 2020 and ended last March 2021. The study was titled, “Exploratory phase 1, randomized, double-blind trial assessing the pharmacokinetic profile, safety and tolerability of a regime of continuous daily administration of Ivermectin to healthy volunteers.” according to the NIH.
There were 24 applicants in total and they were divided into 3 successive cohorts of 8 healthy volunteers (one cohort per dose).
Important Inclusion Criteria:
Subject is male of any ethnic origin.
Subject is aged between 18 to 45 years, inclusive.
Subject has a body mass index (BMI) of 18.5 to 32.0 kg/m2, inclusive.
Subject is ≥50 kg.
Negative reverse transcription polymerase chain reaction (RT-PCR) Test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Screening and negative lateral flow immunoassay test for SARS-CoV-2 at Day -1.
Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examinations, neurological examinations, concomitant medication, vital signs, 12-lead ECG and clinical laboratory evaluations.
Male subjects must use a condom during the study and for 3 months after their final dose of study medication, if their partner is a woman of childbearing potential. In addition, their female partner of childbearing potential must use an additional method of highly effective contraception from first dosing until 3 months following final dosing.
https://www.thegatewaypundit.com/2022/01/research-study-confirms-safety-continuous-administration-ivermectin-study-funded-bill-melinda-gates-foundation/